<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320909">
  <stage>Registered</stage>
  <submitdate>7/12/2009</submitdate>
  <approvaldate>7/01/2010</approvaldate>
  <actrnumber>ACTRN12610000014055</actrnumber>
  <trial_identification>
    <studytitle>Amniotic membrane extract eye drops for eye surface diseases.</studytitle>
    <scientifictitle>The effect of amniotic membrane extract eye drops on promoting epithelialization and suppressing inflammation in patients with ocular surface diseases.</scientifictitle>
    <utrn>U1111-1112-7631</utrn>
    <trialacronym>AME</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>The efficacy of amniotic membrane extract in the treatment of ocular surface diseases with inflammation and epithelial disorders.</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Amniotic membrane extract (AME) eye drops are made from amniotic membrane which has been widely used as a patch or graft for ocular surface diseases. 
AME is applied one drop (0.1ml) every hour for the first week, then every two hours untill complete epithelialization, then 4 times a day untill inflammation subsides.
The patients enrolled might have prior failed amniotic membrane transplantation (AMT).</interventions>
    <comparator>Arm 1: AME in combination with treatments for underlying diseases; 
Arm 2: AMT in combination with treatments for underlying diseases; 
Arm 3: Artificial tears in combination with treatments for underlying diseases.
For AMT, amniotic membrane is secured onto the ocular surface with or without sutures. The procedure requires approximately 30 to 60 minutes.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>mean epithelialization time, the epithelialization is measured by fluorescein stainning under slit lamp examination</outcome>
      <timepoint>every other day during first week, then 2, 3 weeks, 1, 2, 3, 6, 12 months following treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>mean inflammation score</outcome>
      <timepoint>1, 2, 3 weeks, 1, 2, 3, 6, 12 months following treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ocular surface diseases with epithelial disorders and inflammation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>trichiasis, palpebral conjunctiva scar, limbal stem cell dificiency, corneal perforation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Zuguo Liu</primarysponsorname>
    <primarysponsoraddress>54S Xianlie Road, Guangzhou, GD, 510060</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Scientific and Technological Committee of Guangdong Province, China (2006B36006002)</fundingname>
      <fundingaddress>54S Xianlie Road, Guangzhou, GD, 510060</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Zhongshan Ophthalmic Center</sponsorname>
      <sponsoraddress>54S Xianlie Road
Guangzhou 510060</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Now it is well accepted that amniotic membrane transplantation (AMT) as a temporary patch,or as a permanent
graft is effective in treating inflammatory ocular diseases with epithelial defect. We hypothesis that amniotic membrane extract will be equally effective in treating those diseases, and also can avoid the surgical insult to the eye.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Zuguo Liu</name>
      <address>54S Xianlie Road
Guangzhou, GD
510060</address>
      <phone>+86 592 2186 901</phone>
      <fax />
      <email>zuguol@yahoo.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lingyi Liang</name>
      <address>54S Xianlie Road
Guangzhou, GD
510060</address>
      <phone>+86 13829738319</phone>
      <fax />
      <email>lly7399@yahoo.com.cn</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>